Insight, China's Pharmaceutical Industry

SinoMab BioScience Reports Positive Phase I Bridging Data for SM17 – First-in-Class IL-25 Receptor Antibody Advances Route Conversion

SinoMab BioScience Ltd (HKG: 3681) announced positive readouts from a Phase I bridging study in...

InnoCare Pharma Reports 2025 Profitability – Revenue Surges 135% to RMB 2.37B on Global BD Success

Fineline Cube Mar 26, 2026

InnoCare Pharma (HKG: 9969, SHA: 688428) announced 2025 financial results, achieving first-ever annual profitability with...

Company Deals

Insilico Medicine Expands AI Collaboration with Tenacia Bio – $94.75M Deal Targets CNS Drug Discovery with Blood-Brain Barrier Penetration

Fineline Cube Mar 26, 2026

Insilico Medicine (HKG: 3696) and Tenacia Biotechnology, a central nervous system (CNS) specialist, announced an...

Company Deals

Shyndec Pharmaceutical Licenses Eisai Myonal Generic from ScienPharm – RMB 10.5 Million Deal Targets Muscle Relaxant Market

Fineline Cube Mar 25, 2026

Shanghai Shyndec Pharmaceutical Co., Ltd. (SHA: 600420) announced a licensing agreement with Shanghai ScienPharm, obtaining...

Company Deals

MSD Reportedly Eyes $6 Billion Terns Pharma Acquisition – BCR-ABL Inhibitor TERN-701 Targets Post-Keytruda Oncology Pipelinew333333

Fineline Cube Mar 25, 2026

Merck, Sharp & Dohme (MSD; NYSE: MRK) is reportedly preparing to acquire Terns Pharmaceuticals (NASDAQ:...

Company Drug

Zhifei Bio Initiates Phase I Study for DTaP-Hib Quadrivalent Vaccine – Component Combination Targets Pediatric Immunization Compliance

Fineline Cube Mar 25, 2026

Chongqing Zhifei Biological Co., Ltd. (SHE: 300122) announced the initiation of a Phase I clinical...

Company Drug

Changchun High-Tech Wins FDA Orphan Drug Designation for GenSci128 – TP53 Y220C Reactivator Targets Gastric Cancer

Fineline Cube Mar 25, 2026

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that GenSci128 received Orphan...

Policy / Regulatory

China NHC Elevates Chikungunya and SFTS to Category B Status – Enhanced Surveillance and Control Measures Effective April 2026

Fineline Cube Mar 25, 2026

China’s National Health Commission (NHC) announced that chikungunya fever and severe fever with thrombocytopenia syndrome...

Company Drug

Gan & Lee’s Bonfaglutide Wins NMPA Approval for OSA Study – Biweekly GLP‑1 Expands to Sleep Apnea Indication

Fineline Cube Mar 25, 2026

Gan & Lee Pharmaceuticals (SHA: 603087) announced NMPA clinical trial approval to initiate a study...

Company Drug

Clover Bio Reports Positive SCB‑1019 Phase I Data – RSV PreF Vaccine Demonstrates Superior Booster Response vs. GSK’s Arexvy

Fineline Cube Mar 25, 2026

Clover Biopharmaceuticals Ltd. (HKG: 2197) announced additional positive Phase I data from its US clinical...

Company

Merck KGaA Inaugurates China R&D Center – Beijing BioPark Hub Targets First‑Tier Global Drug Launch Status

Fineline Cube Mar 25, 2026

Merck KGaA (ETR: MRK) announced the inauguration of its China R&D Center at the BioPark...

Company

Atom Therapeutics Files Hong Kong IPO – URAT1 Inhibitor ABP-671 Targets First‑Line Gout Treatment Market

Fineline Cube Mar 25, 2026

Atom Therapeutics Co., Ltd. has submitted an initial public offering (IPO) filing to the Hong...

Company Deals

Asieris Pharma Partners with SPH Keyuan to Commercialize Cevira – World’s First Non‑Surgical Cervical Precancer Treatment Launches in China

Fineline Cube Mar 25, 2026

Jiangsu Asieris Pharmaceuticals Co., Ltd. (SHA: 688176), a urogenital cancer specialist, has entered into a...

Company Drug

Henlius Biotech Wins Health Canada Approval for Denosumab Biosimilars – Bildyos and Tuzemty Expand Organon Partnership to Canada

Fineline Cube Mar 25, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced marketing approval from Health Canada for Bildyos (denosumab...

Company Drug

Qilu Pharma’s QLS31905 Wins FDA Orphan Drug Designation – First‑in‑Class Claudin18.2/CD3 Bispecific Enters Phase III for Pancreatic Cancer

Fineline Cube Mar 25, 2026

Qilu Pharmaceutical Co., Ltd. announced that QLS31905, its Claudin18.2/CD3 bispecific T‑cell engager (BsAb), has received...

Company

WuXi Biologics Reports 2025 Revenue Growth 16.7% – Net Profit Surges 46.3% on Record 209 New Projects

Fineline Cube Mar 25, 2026

WuXi Biologics Co., Ltd. (HKG: 2269) announced strong 2025 annual results, with total revenue rising...

Company Drug

Bayer/Regeneron’s Eylea HD Wins Japan Approval for RVO – Third Indication Nod with Extended Dosing Demonstrates 3 Fewer Injections

Fineline Cube Mar 25, 2026

Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Eylea HD (aflibercept) injection 8...

Company Deals

Sciwind Biosciences Files Hong Kong IPO Prospectus – GLP‑1 Obesity Pipeline Targets R&D Funding for Weight Management Franchise

Fineline Cube Mar 25, 2026

Sciwind Biosciences Co., Ltd. has submitted its prospectus to the Hong Kong Stock Exchange, seeking...

Company Drug

Sanofi’s Dupixent Wins Japan Approval for Bullous Pemphigoid – Seventh Indication Expands IL‑4/IL‑13 Franchise

Fineline Cube Mar 25, 2026

Sanofi S.A. (NASDAQ: SNY) announced that Dupixent (dupilumab) has received marketing approval from Japan’s Ministry...

Company Drug

Haixi Pharma Advances HXP056 to Phase II – Oral Multi‑Selective Therapy for Wet AMD and Hemorrhagic Retinal Diseases

Fineline Cube Mar 25, 2026

Fujian Haixi Pharmaceuticals Co., Ltd. (HKG: 2637) announced the initiation of a Phase II clinical...

Insight, China's Pharmaceutical Industry

Servier Group Partners with n-Lorem Foundation to Develop ASO Therapies for Rare Neurodevelopmental Disorders

Shanghai Juncell Therapeutics Files for HKEX Listing with Breakthrough TIL Therapy GC101 for Solid Tumors

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets

AstraZeneca Joins ZERO Prostate Cancer’s Blitz the Barriers Initiative – Ambitious Program Aims to Save 100,000 Lives by 2035

GSK’s Momelotinib Receives Orphan Drug Designation from FDA and EMA for VEXAS Syndrome, Addressing Critical Unmet Need in Rare Myeloid Disorder

Regent Pacific’s Senstend Receives NMPA Approval with Four-Year Data Protection, Triggering $5M Milestone Payment from Wanbang

SinoMab BioScience Reports Positive Phase I Bridging Data for SM17 – First-in-Class IL-25 Receptor Antibody Advances Route Conversion

InnoCare Pharma Reports 2025 Profitability – Revenue Surges 135% to RMB 2.37B on Global BD Success

Insilico Medicine Expands AI Collaboration with Tenacia Bio – $94.75M Deal Targets CNS Drug Discovery with Blood-Brain Barrier Penetration

Shyndec Pharmaceutical Licenses Eisai Myonal Generic from ScienPharm – RMB 10.5 Million Deal Targets Muscle Relaxant Market

MSD Reportedly Eyes $6 Billion Terns Pharma Acquisition – BCR-ABL Inhibitor TERN-701 Targets Post-Keytruda Oncology Pipelinew333333

Zhifei Bio Initiates Phase I Study for DTaP-Hib Quadrivalent Vaccine – Component Combination Targets Pediatric Immunization Compliance

Changchun High-Tech Wins FDA Orphan Drug Designation for GenSci128 – TP53 Y220C Reactivator Targets Gastric Cancer

China NHC Elevates Chikungunya and SFTS to Category B Status – Enhanced Surveillance and Control Measures Effective April 2026

Gan & Lee’s Bonfaglutide Wins NMPA Approval for OSA Study – Biweekly GLP‑1 Expands to Sleep Apnea Indication

Clover Bio Reports Positive SCB‑1019 Phase I Data – RSV PreF Vaccine Demonstrates Superior Booster Response vs. GSK’s Arexvy

Merck KGaA Inaugurates China R&D Center – Beijing BioPark Hub Targets First‑Tier Global Drug Launch Status

Atom Therapeutics Files Hong Kong IPO – URAT1 Inhibitor ABP-671 Targets First‑Line Gout Treatment Market

Asieris Pharma Partners with SPH Keyuan to Commercialize Cevira – World’s First Non‑Surgical Cervical Precancer Treatment Launches in China

Henlius Biotech Wins Health Canada Approval for Denosumab Biosimilars – Bildyos and Tuzemty Expand Organon Partnership to Canada

Qilu Pharma’s QLS31905 Wins FDA Orphan Drug Designation – First‑in‑Class Claudin18.2/CD3 Bispecific Enters Phase III for Pancreatic Cancer

WuXi Biologics Reports 2025 Revenue Growth 16.7% – Net Profit Surges 46.3% on Record 209 New Projects

Bayer/Regeneron’s Eylea HD Wins Japan Approval for RVO – Third Indication Nod with Extended Dosing Demonstrates 3 Fewer Injections

Sciwind Biosciences Files Hong Kong IPO Prospectus – GLP‑1 Obesity Pipeline Targets R&D Funding for Weight Management Franchise

Sanofi’s Dupixent Wins Japan Approval for Bullous Pemphigoid – Seventh Indication Expands IL‑4/IL‑13 Franchise

Haixi Pharma Advances HXP056 to Phase II – Oral Multi‑Selective Therapy for Wet AMD and Hemorrhagic Retinal Diseases

You Missed

GSK’s Momelotinib Receives Orphan Drug Designation from FDA and EMA for VEXAS Syndrome, Addressing Critical Unmet Need in Rare Myeloid Disorder

Regent Pacific’s Senstend Receives NMPA Approval with Four-Year Data Protection, Triggering $5M Milestone Payment from Wanbang

Bayer AG Inaugurates Second Consumer Health Innovation Center in China, Expanding Skin and Digestive Health Partnerships

Shanghai Henlius Biotech Receives Australian Clearance for Phase II Study of PD-L1 ADC HLX43 Combined with Hansizhuang in NSCLC Neoadjuvant Therapy